{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T04:05:11Z","timestamp":1743307511068,"version":"3.40.3"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2004,4,20]],"date-time":"2004-04-20T00:00:00Z","timestamp":1082419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,5]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Antiretroviral therapy is not uncommonly associated with drug toxicities, and hepatotoxicity occurs in approximately 20% of individuals prescribed antiretroviral therapy. Mitochondrial toxicity causing lactic acidosis is a rare but fatal complication that has been described in some HIV-infected patients treated with nucleoside analogue reverse transcriptase inhibitors. In this report, we describe the course of an HIV-infected patient receiving antiretroviral therapy who developed lactic acidosis after liver transplantation for HCV-induced liver disease. (Liver Transpl 2004;10:699-702.)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.20109","type":"journal-article","created":{"date-parts":[[2004,4,20]],"date-time":"2004-04-20T16:34:30Z","timestamp":1082478870000},"page":"699-702","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["Mitochondrial toxicity associated with HAART following liver transplantation in an HIV-infected recipient"],"prefix":"10.1097","volume":"10","author":[{"given":"Charalambos","family":"Antoniades","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Knisely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Norris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-17-20250326","doi-asserted-by":"crossref","first-page":"853860","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"R2-17-20250326","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/gut.51.4.601","article-title":"Hepatitis C and HIV-1 co-infection.","volume":"51","author":"Mohsen","year":"2002","journal-title":"Gut"},{"key":"R3-17-20250326","doi-asserted-by":"crossref","first-page":"211217","DOI":"10.1097\/00126334-200007010-00003","article-title":"Mortality from liver disease in patients with HIV infection: A cohort study.","volume":"24","author":"Puoti","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R4-17-20250326","first-page":"49297","article-title":"Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.","volume":"32","author":"Rica","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R5-17-20250326","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1023\/A:1007506617734","article-title":"Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users.","volume":"15","author":"Soriano","year":"1999","journal-title":"Eur J Epidemiol"},{"key":"R6-17-20250326","doi-asserted-by":"crossref","first-page":"17351744","DOI":"10.1097\/00002030-199814000-00004","article-title":"Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as a common pathway.","volume":"12","author":"Brinkman","year":"1998","journal-title":"AIDS"},{"key":"R7-17-20250326","doi-asserted-by":"crossref","first-page":"182189","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections.","volume":"35","author":"Sulkowski","year":"2002","journal-title":"Hepatology"},{"key":"R8-17-20250326","doi-asserted-by":"crossref","first-page":"838846","DOI":"10.1086\/339041","article-title":"Severe nucleoside-associated lactic acidosis in HIV-infected patients: Report of 12 cases and review of the literature.","volume":"34","author":"Falco","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R9-17-20250326","doi-asserted-by":"crossref","first-page":"13411349","DOI":"10.1097\/00002030-200207050-00005","article-title":"Hyperlactemia and lactic acidosis during antiretroviral therapy; relevance, reproducibility, and possible risk factor.","volume":"16","author":"Moyle","year":"2002","journal-title":"AIDS"},{"key":"R10-17-20250326","doi-asserted-by":"crossref","first-page":"14231430","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy.","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"key":"R11-17-20250326","doi-asserted-by":"crossref","first-page":"162166","DOI":"10.1086\/313912","article-title":"Hyperlactatemia and hepatic abnormalities in ten HIV-infected patients taking multiple nucleoside analogues.","volume":"31","author":"Lonergan","year":"2000","journal-title":"Clin Infect Dis"},{"key":"R12-17-20250326","doi-asserted-by":"crossref","first-page":"13241328","DOI":"10.1086\/374601","article-title":"Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: A case-control study.","volume":"36","author":"Bonnet","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R13-17-20250326","doi-asserted-by":"crossref","first-page":"19141921","DOI":"10.1086\/323783","article-title":"Symptomatic lactic acidosis in hospitalised antiretroviral-treated patients with HIV infection: a report of 12 cases.","volume":"33","author":"Coghlan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R14-17-20250326","doi-asserted-by":"crossref","first-page":"370375","DOI":"10.1097\/01.TP.0000075973.73064.A6","article-title":"Kidney and liver transplantation in HIV-infected patients: A pilot safety and efficacy study.","volume":"76","author":"Stock","year":"2003","journal-title":"Transplantation"},{"key":"R15-17-20250326","first-page":"391396","article-title":"Mycophenolate mofetil in renal transplantation: 3 year results from the placebo-controlled trial.","volume":"68","year":"1999","journal-title":"Transplantation"},{"key":"R16-17-20250326","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1016\/S0166-3542(02)00006-2","article-title":"Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir.","volume":"55","author":"Hossain","year":"2002","journal-title":"Antivir Res"},{"key":"R17-17-20250326","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1097\/00126334-200209010-00006","article-title":"The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA.","volume":"31","author":"Margolis","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R18-17-20250326","doi-asserted-by":"crossref","first-page":"20032005","DOI":"10.1111\/j.1572-0241.1999.01294.x","article-title":"Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: Ultrastructural and biochemical changes.","volume":"94","author":"Barbaro","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"R19-17-20250326","doi-asserted-by":"crossref","first-page":"13581364","DOI":"10.1053\/jhep.2001.24432","article-title":"Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity.","volume":"33","author":"Adinolfi","year":"2001","journal-title":"Hepatology"},{"key":"R20-17-20250326","doi-asserted-by":"crossref","first-page":"811820","DOI":"10.1056\/NEJMoa012035","article-title":"Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.","volume":"346","author":"Cote","year":"2002","journal-title":"N Engl J Med"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.20109","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.20109","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-200405000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T08:15:25Z","timestamp":1743236125000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-200405000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.20109","relation":{},"ISSN":["1527-6465"],"issn-type":[{"type":"print","value":"1527-6465"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}